CartilaGen

CartilaGen is pioneering a first-in-category therapeutic approach to prevent Post-Traumatic Osteoarthritis (PTOA), a debilitating and costly sequela of joint injuries like ankle fractures. Its lead candidate, CG-001, is an intra-articular injection of amobarbital that inhibits mitochondrial Complex I to reduce reactive oxidant species (ROS) and cartilage damage immediately following injury. The company has completed a Phase 1 safety trial, secured Department of Defense funding for a Phase 2 efficacy study, and holds intellectual property protection extending to 2044, targeting a significant unmet need with a seamless surgical workflow integration.

Targeted inhibition of mitochondrial Complex I (using amobarbital) to reduce reactive oxidant species (ROS) and oxidative stress in chondrocytes immediately following traumatic joint injury, aiming to prevent cartilage degeneration and Post-Traumatic Osteoarthritis.

There are currently no approved therapies specifically for the prevention of Post-Traumatic Osteoarthritis, making CG-001 a potential first-in-category therapeutic. Competition is indirect, consisting of the standard of care (surgery alone) and later-stage symptomatic treatments for established osteoarthritis (pain relievers, joint replacements).